{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06437574",
            "orgStudyIdInfo": {
                "id": "STUDY00003290"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01CA280060",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01CA280060"
                }
            ],
            "organization": {
                "fullName": "Cedars-Sinai Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer",
            "officialTitle": "Lowering Cholesterol in Prostate Cancer to Target Rapamycin-Insensitive Companion Of MTOR (TORC2) in T-Cell Surface Glycoprotein CD8 Alpha Chain (CD8+) Lymphocytes",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "intensive-cholesterol-lowering-and-t-cells-in-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-02-29",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-05-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-23",
            "studyFirstSubmitQcDate": "2024-05-29",
            "studyFirstPostDateStruct": {
                "date": "2024-05-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Hyung L. Kim, MD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Cedars-Sinai Medical Center"
            },
            "leadSponsor": {
                "name": "Cedars-Sinai Medical Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 months. Eligible patients will initiate iCL with Vytorin\u00ae(group 1, 2, and 3), an FDA-approved combination of ezetimibe and simvastatin used to lower atherogenic low density lipoprotein cholesterol (LDL-C) or Ezetimibe (group 4). Starting dose will be determined by current statin use and LDL-C levels. Dose modifications of VYTORIN will be employed with the goal of achieving LDL-C \\<70 mg/dl. Dose adjustment is not allowed for ezetimibe."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intensive Lipid Lowering",
                    "type": "EXPERIMENTAL",
                    "description": "Single arm with dual agents (ezetimibe and simvastatin) target the two primary sources of cholesterol, absorption in the gut and synthesis in the liver. These 2 agents are available in a single pill that is FDA approved and sold under the trade name, Vytorin.",
                    "interventionNames": [
                        "Drug: Vytorin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Vytorin",
                    "description": "Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.",
                    "armGroupLabels": [
                        "Intensive Lipid Lowering"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pre/Post-change in percent prostate infiltrating CD8+ T lymphocytes.",
                    "description": "Our primary hypothesis is that maximum cholesterol lowering will increase CD8+ memory T cells and increase CD8+ T cell infiltration into prostate tissue. Change in CD8+ T cells in the prostate from baseline to 3 to 6 months is the primary endpoint.",
                    "timeFrame": "3 to 6 months of cholesterol-lowering intervention"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. At least one Atherosclerotic Cardiovascular Disease (ASCVD) risk factor, such as:\n\n   1. \u2265 50 years of age\n   2. Hypertension\n   3. Hypercholesterolemia\n   4. Diabetes\n   5. Current or former smoker\n   6. First-degree family history of any cardiovascular heart disease\n   7. BMI \\> 25\n   8. On hypertension treatment, statin, and/or aspirin therapy\n4. Patients with clinically localized prostate cancer. That is Low or intermediate risk prostate cancer de\ufb01ned as:\n\n   1. Pre-operative PSA (Prostate Specific Antigen) \u2264 20.0 ng/ml\n   2. Clinical stage T1c or cT2\n   3. Gleason score 3+3 or 3+4 or 4+3\n5. Patients on AS with plans for surveillance biopsy\n6. No previous treatment for prostate cancer with radiotherapy, chemotherapy, or hormonal therapy\n7. Ability to take oral medication and be willing to adhere to once daily, oral Vytorin or ezetimibe.\n8. Agree to avoid consumption of grapefruit and grapefruit juice \u2265 one quart per day throughout study duration.\n\nExclusion Criteria:\n\n1. Current use of medications contraindicated for use with a statin such as strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone).\n2. Current use of medications contraindicated for use with ezetimibe (i.e., gemfibrozil, cyclosporine, or danazol).\n3. History of allergic or severe reaction to a either study agent.\n4. History of moderate or severe myalgia with statin use.\n5. Acute liver failure or decompensated cirrhosis\n6. Already on maximum VYTORIN dose (10/80)\n7. Already on a PCSK9 inhibitor",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amy Hoang",
                    "role": "CONTACT",
                    "phone": "310-423-1542",
                    "email": "Amy.Hoang@cshs.org"
                },
                {
                    "name": "Laura Sarmiento",
                    "role": "CONTACT",
                    "phone": "310-423-4295",
                    "email": "Laura.Sarmiento@cshs.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Hyung Kim, MD",
                    "affiliation": "Cedars-Sinai Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cedars-Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amy Hoang",
                            "role": "CONTACT",
                            "phone": "310-423-1542",
                            "email": "Amy.Hoang@cshs.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069499",
                    "term": "Ezetimibe, Simvastatin Drug Combination"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000924",
                    "term": "Anticholesteremic Agents"
                },
                {
                    "id": "D000000960",
                    "term": "Hypolipidemic Agents"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000057847",
                    "term": "Lipid Regulating Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21960",
                    "name": "Sirolimus",
                    "relevance": "LOW"
                },
                {
                    "id": "M409",
                    "name": "Ezetimibe",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                },
                {
                    "id": "M450",
                    "name": "Ezetimibe, Simvastatin Drug Combination",
                    "asFound": "Reviewing",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21713",
                    "name": "Simvastatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M353695",
                    "name": "Temsirolimus",
                    "relevance": "LOW"
                },
                {
                    "id": "M2827",
                    "name": "MTOR Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M340819",
                    "name": "polysaccharide-K",
                    "relevance": "LOW"
                },
                {
                    "id": "M4243",
                    "name": "Anticholesteremic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4278",
                    "name": "Hypolipidemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M28883",
                    "name": "Lipid Regulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Lipd",
                    "name": "Lipid Regulating Agents"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                }
            ]
        }
    },
    "hasResults": false
}